Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
A

Ratings ESG MSCI

Ratings Mycronic AB: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Highlights: Mycronic AB
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: Mycronic AB
  • The firm trades with high earnings multiples: 32.69 times its 2026 earnings per share.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Rating Financials

Mycronic AB SectorSweden

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

-

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Mycronic AB SectorSweden

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Mycronic AB SectorSweden

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Mycronic AB SectorSweden

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Mycronic AB SectorSweden

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
5.93B
A
676B
AAA
413B
AAA
200B
AAA
91.37B
A
27.2B -
24.72B
A
20.78B
BBB
20.68B
BBB
16.37B
BBB
Average 149.53B
AA
Weighted average by Cap.
AA